Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing...

Area of Science:

• Gastroenterology
• Pharmacology
• Computational Biology

Background:

• Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition.
• Current IBD therapeutic strategies often target inflammation or the epithelial barrier separately.
• Dual-targeting approaches for inflammation and epithelial barrier integrity represent a promising therapeutic strategy.

Purpose of the Study:

• To identify novel drug candidates for IBD by simultaneously targeting inflammation and the epithelial barrier.
• To investigate the potential of inhibiting phosphodiesterase 4 (PDE4) and prolyl hydroxylase domain enzymes 1 and 2 (PHD1/2) for IBD treatment.
• To evaluate the binding efficacy of identified compounds against key IBD therapeutic targets.

Main Methods:

• Virtual screening and molecular docking were employed to identify potential drug candidates.
• Molecular dynamics simulations were used to assess the stability and binding interactions of the compounds.
• The study focused on three targets: PDE4, PHD1, and PHD2, crucial for inflammation and epithelial barrier function.

Main Results:

• Five compounds—Cassiamin C, Ginkgetin, Hinokiflavone, Sciadopitysin, and Sojagol—were identified as potential IBD drug candidates.
• All identified compounds, except Sojagol for PDE4B, exhibited superior free binding energy compared to reference ligands.
• Ginkgetin demonstrated the highest potential for targeting multiple drug targets, indicating broad therapeutic applicability.

Conclusions:

• The identified compounds represent promising novel therapeutic agents for managing inflammatory bowel disease.
• Ginkgetin shows particular promise as a multi-target therapeutic for IBD.
• Further experimental validation is required to confirm the efficacy and safety of these compounds in preclinical and clinical settings.